EPFL researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. The work, covered in two papers, turns the previously lab-based method into a full-blown immunotherapy strategy.

Lymphedema after head and neck cancer is considerably more common than previously assumed and can persist long after cancer treatment has finished. Researchers at Lund University in Sweden have discovered that patients with a low level of physical activity face a higher risk of developing lymphedema. They have also noted that a lymph scanner objectively measures changes in the condition – a method that has now been introduced in Sweden’s Southern Healthcare Region.

BUFFALO, NY – December 17, 2025 – A new research paper was published in Oncotarget (Volume 16) on December 15, 2025, titled “Machine learning-based survival prediction in colorectal cancer combining clinical and biological features.”

A research group at the Italian Institute of Technology (Istituto Italiano di Tecnologia - IIT) has identified a candidate molecule that could improve current therapies against pancreatic cancer. The team designed the new molecule, called Apt1, using artificial intelligence tools and tested it in in vitro experiments, demonstrating its effectiveness in making tumour cells more vulnerable to chemotherapy drugs. When combined with drugs already in use, the molecule increases the effectiveness of anticancer therapies even at lower dosages than those normally given. The research study has been published in the scientific journal Nature Communications.

Compared with white patients, Black patients with an aggressive form of leukemia--called acute myeloid leukemia (AML)--were on average more than five years younger at diagnosis and more than 30 percent more likely to die of their disease; that is according to a new analysis of data led by University of Maryland School of Medicine researchers. The study, supported by the National Cancer Institute (NCI), also found that Black patients were more than 20 percent more likely to die of any cause over the 34-year study period. Among patients with a mutation in their cancer cells that is generally associated with more favorable outcomes from treatment, survival for Black patients was less than half that of white patients.